Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies

Mantia-Smaldone, GM and Edwards, RP and Vlad, AM (2011) Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies. Cancer Management and Research, 3 (1). 25 - 38.

Preview	PDF Available under License : See the attached license file. Download (228kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have subsequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials. © 2011 Mantia-Smaldone et al, publisher and licensee Dove Medical Press Ltd.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Mantia-Smaldone, GM Edwards, RP rpe1@pitt.edu RPE1 0000-0003-0370-1390 Vlad, AM anvst12@pitt.edu ANVST12
Date:	31 January 2011
Date Type:	Publication
Journal or Publication Title:	Cancer Management and Research
Volume:	3
Number:	1
Page Range:	25 - 38
Refereed:	Yes
Article Type:	Review
Date Deposited:	12 Dec 2012 20:49
Last Modified:	23 Jan 2019 05:55
URI:	http://d-scholarship.pitt.edu/id/eprint/16858

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

---

Actions (login required)

View Item